Colon cancer patients taking glp1 agonist drugs were less than half as likely to die after 5 years, compared to those not taking the drugs.
Once again, we see the power of calorie restriction and weight loss in humans.
Louis shares a FoundMyFitness post on a study suggesting GLP-1 drugs lower colon cancer mortality, especially in the most obese.
Colon cancer patients taking glp1 agonist drugs were less than half as likely to die after 5 years, compared to those not taking the drugs.
Once again, we see the power of calorie restriction and weight loss in humans.
Recent research is showing that some of these weight loss drugs GLP-1 receptor agonists, which include Ozempic and things like Wegovy may decrease cancer mortality. The people who are most obese benefit the most.
The effects were big.
Colon cancer patients taking GLP-1 drugs (Ozempic, Wegovy, Mounjaro) were less than half as likely to die within 5 years.
This new study suggests GLP-1 drugs might specifically target obesity-driven inflammatory and metabolic pathways known to accelerate colon cancer progression.
There are several mechanisms by which GLP-1 agonists may suppress tumor growth, including weight loss, improving glucose regulation and insulin sensitivity, and lowering inflammation.
There is also some interesting in-vitro cell culture data indicating that these drugs may directly slow cancer cell proliferation, induce apoptosis, and remodel the tumor microenvironment itself.
So what’s the take-away? Should everyone be on these drugs? Absolutely not. Weight loss is critical. Ideally, diet and lifestyle changes would drive it, but clearly, we’re losing that fight in the US, where obesity contributes to at least 13 types of cancer and many other diseases.
In this study, the greatest benefit from GLP-1 drugs was seen in people with obesity, exactly those who struggle most to lose weight through lifestyle alone.
I think the GLP-1s represent a potential tool, particularly when traditional methods have repeatedly failed some people.
Study title:
The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients